By
AmyT on
December 2, 2011
Yesterday marks “a milestone” in the development of new technology to help automate the care and treatment of type 1 diabetes, according to JDRF!
The U.S. Food and Drug Administration unveiled its eagerly awaited Draft Guidance document for research and development of the Artificial Pancreas system, and initial reaction from JDRF — in a press conference held yesterday afternoon — was a mix of jubilation and a more measured response that they remain “guardedly optimistic” about the details…
Read more »
By
AmyT on
November 29, 2011
Ten days ago, I got a last-minute invitation to attend a small Bay Area JDRF event at the Four Seasons Hotel in Palo Alto, in the heart of Silicon Valley. This is where technology happens. It turns out, this diabetes-tech-update event has been going on for a few years. I was especially excited, because the theme of this year’s program was FDA Reform: How Can We Remain Competitive While Protecting Public Safety? Now that sounded…
Read more »
It’s not too often we have a new insulin making its way on the scene, so we were excited to hear that Novo Nordisk filed two applications with the FDA for a new “ultra long acting” insulin called Degludec, and another for something called DegludecPlus, a combination of degludec and insulin aspart (Novolog), which would be available in an insulin pen in a fixed 70% degludec/30% Novolog ratio. The company is hoping for FDA approval…
Read more »
True or false: It’s illegal for U.S. residents to order and receive prescription medication from pharmacies in Canada.
The answer: True!
Okay, how about this one -
True or false: It’s illegal for Canadian pharmacies to ship prescription medications to U.S. residents.
The answer: False!
Did you get all that? Allow me to explain…
So, a couple of weeks ago the news broke that Google got into heaps of trouble with the FDA for allowing…
Read more »
